Department of Internal Medicine and Biomedical Science University Hospital of Parma, 43100 Parma, Italy.
Curr Pharm Des. 2011 Oct;17(30):3252-7. doi: 10.2174/138161211797904181.
The introduction of stem cells in cardiology provides new tools in understanding the regenerative processes of the normal and pathologic heart and opens new options for the treatment of cardiovascular diseases. The feasibility of adult bone marrow autologous and allogenic cell therapy of ischemic cardiomyopathies has been demonstrated in humans. However, many unresolved questions remain to link experimental with clinical observations. The demonstration that the heart is a self-renewing organ and that its cell turnover is regulated by myocardial progenitor cells offers novel pathogenetic mechanisms underlying cardiac diseases and raises the possibility to regenerate the damaged heart. Indeed, cardiac stem progenitor cells (CSPCs) have recently been isolated from the human heart by several laboratories although differences in methodology and phenotypic profile have been described. The present review points to the potential role of CSPCs in the onset and development of congestive heart failure and its reversal by regenerative approaches aimed at the preservation and expansion of the resident pool of progenitors.
心脏干细胞的引入为理解正常和病理性心脏的再生过程提供了新的工具，并为心血管疾病的治疗开辟了新的选择。在人类中已经证明了成人骨髓自体和同种异体细胞治疗缺血性心肌病的可行性。然而，仍有许多悬而未决的问题有待将实验观察与临床观察联系起来。心脏是一个自我更新的器官，其细胞更替受心肌祖细胞调节的证明，为心脏疾病的发病机制提供了新的认识，并为心脏损伤的再生提供了可能性。事实上，最近几个实验室已经从人类心脏中分离出心脏干细胞祖细胞（CSPCs），尽管在方法学和表型特征方面存在差异。本综述指出了 CSPCs 在充血性心力衰竭的发生和发展中的潜在作用，以及通过旨在保存和扩增驻留祖细胞池的再生方法来逆转心力衰竭的可能性。
